A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People

Phase 1

Not yet recruiting

• Conditions: Healthy Volunteers; Chronic Kidney Disease
• Interventions: Drug: NNC0705-0001; Drug: Placebo

• Registration Number: NCT07029568
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

The study is testing a new study medicine (called NNC0705-0001), as a potential medicine to treat chronic systemic inflammation, which is known for increasing the risk of developing cardiometabolic diseases. The aim of this study is to see if the study medicine is safe, how it works in our body, and what our body does to the study medicine. The participant will either get NNC0705-0001 or placebo (a "dummy medicine" without the active ingredient). Which treatment the participant gets is decided by chance. The study consists of 3 parts: PART A - single ascending dose (SAD); PART B - multiple ascending doses (MAD) and PART C - food effect (FE) on the pharmacokinetic (PK) properties of NNC0705-0001 and will last about 35 days (PART A) and 41 days (PART B and C).

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-11
• Study First Submitted QC: 2025-06-11
• Last Update Submitted: 2025-06-11
• Study Start: 2025-06-13
• Study First Posted: 2025-06-19
• Last Update Posted: 2025-06-19
• Primary Completion: 2026-07-22
• Study Completion: 2026-07-22

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

• Men, or women of non-childbearing potential.
• Age 18-55 years (both inclusive) at the time of signing the informed consent.
• Body mass index (BMI) between 18.5 to 29.9 kilogram per meter square (kg/m^2) (both inclusive) at screening.
• Body weight: greater than or equal to (≥) 50 kilogram (kg) at screening.
• Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion Criteria

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
• Any of the below laboratory safety parameters at screening outside normal range, see designated reference range documents for specific values; Alanine Aminotransferase (ALT) greater than (>) Upper limit of normal (ULN); Aspartate aminotransferase (AST) > ULN; Total Bilirubin (BIL) > ULN; Creatinine > ULN; International normalized ratio (INR) > ULN; High-Sensitivity C-Reactive Protein (hsCRP) > 5 milligram per liter (mg/L) (males) and > 8 mg/L (females)
• Use of prescription medicinal products or vaccines within 14 days before dosing and/or non-prescription medicinal products within 7 days before dosing. Exceptions are: Topical medications not reaching systemic circulation; less than once per week of over the counter paracetamol and/or acetylsalicylic acid at their labelled doses for mild pain; vitamins at their labelled doses.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Part A: NNC0705-0001	NNC0705-0001	Participants will receive 6 different single ascending doses of NNC0705-0001 via oral administration.
Part A: Placebo	Placebo	Participants will receive single ascending dose of placebo matching NNC0705-0001 via oral administration.
Part B: Placebo	Placebo	Participants will receive multiple ascending doses of placebo matching NNC0705-0001 via oral administration.
Part B: NNC0705-0001	NNC0705-0001	Participants will receive 4 different multiple ascending doses of NNC0705-0001 via oral administration.
Part C: NNC0705-0001	NNC0705-0001	Participants will receive 2 separate single doses of NNC0705-0001 at a previously safety-cleared dose level in PART A, either in a fed or fasted state.

Primary Outcome Measures

Name	Time	Method
PART A: Number of treatment emergent adverse events (TEAE)	From time of dosing (day 1) to end of study (day 7)	Measured in number of events.
PART B: Number of TEAEs	From time of dosing (day 1) to end of study (day 13)	Measured in number of events.
AUC, SD; the area under the NNC0705-0001 plasma concentration-time curve after a single dose	From pre-dose (day 1 or day 8) to day 2 or day 9	Measured in Hour x Micromole (hr×μM).

Secondary Outcome Measures

Name	Time	Method
PART A: AUC0-t, SD; the area under the NN0705-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration after a single dose	From pre-dose (day 1) to day 5	Measured in hr×μM.
PART A: AUC0-∞, SD; the area under the NNC0705-0001 plasma concentration-time curve from time 0 to infinity after a single dose	From pre-dose (day 1) to day 5	Measured in hr×μM.
PART A: Cmax, SD; the maximum plasma concentration of NNC0705-0001 after a single dose	From pre-dose (day 1) to day 5	Measured in micromole (μM).
PART B: AUCtau, MD; the area under the NN0705-0001 plasma concentration-time curve from time 0 to tau after the last dose	From pre-dose (day 7) to end of study (day 13)	Measured in hr×μM.
PART B: Cmax, MD; the maximum plasma concentration of NNC0705-0001 after last dose	From pre-dose (day 7) to end of study (day 13)	Measured in μM.
PART C: Cmax, SD; the maximum plasma concentration of NNC0705-0001 after a single dose	From pre-dose (day 1 or day 8) to day 2 or day 9	Measured in μM.
PART C: Number of TEAEs	From time of dosing (day 1) to end of study (day 12)	Measured in number of events.

Trial Locations

Locations (1)

ICON - location Groningen; 🇳🇱 Groningen, Netherlands